Skip to content

US · PHAT · BIOTECHNOLOGY

Phathom Pharmaceuticals, Inc. (PHAT) intrinsic value and stock valuation

$4.66as of 2026-11-21 · Mkt cap 665.81M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Phathom Pharmaceuticals, Inc. DCF and intrinsic value

InvestorsCraft values PHAT with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from PHAT’s statements →

Phathom Pharmaceuticals, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Florham Park, NJ 07932 phathompharma.com

How the business is doing

Fiscal 2018–2025, USD

Revenue
$175.1M
20182025
Net income
-$-221.25M
20182025
Free cash flow
-$-166.78M
20182025
Total equity
-$-438.17M
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$175.1M$55.3M$680K$0.00$0.00
Operating income-$-159.99M-$-277.47M-$-167.31M-$-172.44M-$-135.08M
Net income-$-221.25M-$-334.33M-$-201.59M-$-197.72M-$-143.88M
EPSd-$-3.03M-$-5.29M-$-3.93M-$-5.05M-$-3.89M
Operating cash flow-$-166.78M-$-266.77M-$-137.58M-$-146.53M-$-148.46M
Capital expenditure-$-230K-$-140K-$-1.63M-$-1.04M-$-330K
Free cash flow-$-166.78M-$-266.9M-$-139.21M-$-147.57M-$-148.78M
Total assets$259.2M$378.3M$413.8M$164.8M$189.4M
Total debt$211.8M$201.9M$139M$97.1M$91.3M
Net debt$81.8M-$-95.35M-$-242.36M-$-58.31M-$-91.92M
Total equity-$-438.17M-$-253.58M-$-72.76M-$-74.81M$72.2M
Cash and short-term investments$130M$297.3M$381.4M$155.4M$183.3M
Income statement
20252024202320222021
Revenue$175.1M$55.3M$680K$0.00$0.00
Cost of revenue$22.6M$7.97M$170K$620K$520K
Gross profit$152.5M$47.3M$520K-$-620K-$-520K
Research and development expenses$32.8M$34.1M$49.9M$71.4M$72.3M
Selling, general and administrative expenses$279.7M$290.7M$117.9M$100.4M$62.2M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$312.5M$324.8M$167.8M$171.8M$134.6M
Cost and expenses$335.1M$332.7M$168M$172.4M$135.1M
Interest income$7.04M$15.2M$7.88M$2.13M$40K
Interest expense$68.1M$72M$42M$27.3M$6.79M
Depreciation and amortization$630K$800K$570K$620K$520K
Ebitda-$-152.5M-$-261.52M-$-159.05M-$-169.8M-$-136.57M
Operating income-$-159.99M-$-277.47M-$-167.31M-$-172.44M-$-135.08M
Total other income/expenses, net-$-61.26M-$-56.86M-$-34.28M-$-25.28M-$-8.8M
Income before tax-$-221.25M-$-334.33M-$-201.59M-$-197.72M-$-143.88M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-221.25M-$-334.33M-$-201.59M-$-197.72M-$-143.88M
Weighted average shares outstanding$72.9M$63.2M$51.3M$39.1M$37M
Weighted average diluted shares outstanding$72.9M$63.2M$51.3M$39.1M$37M
Balance sheet
20252024202320222021
Cash and short-term investments$130M$297.3M$381.4M$155.4M$183.3M
Net receivables$78.1M$38.8M$1.64M$0.00$0.00
Inventory$5.52M$3.21M$1.21M$0.00$0.00
Total current assets$229M$360.1M$397.4M$160.5M$186.5M
Property, plant and equipment, net$3.67M$2.09M$3.62M$3.49M$2.56M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$510K$0.00
Total non-current assets$30.2M$18.2M$16.4M$4.3M$2.9M
Total assets$259.2M$378.3M$413.8M$164.8M$189.4M
Accounts payable$4.98M$10.5M$12.6M$10M$5.15M
Short-term debt$650K$500K$730K$710K$490K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$132M$85.7M$38.8M$26.2M$18.9M
Long-term debt$211.2M$201.4M$138.3M$96.4M$90.9M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$565.3M$546.2M$447.8M$213.4M$98.4M
Capital lease obligations$2.71M$500K$1.19M$1.81M$1.67M
Total liabilities$697.3M$631.9M$486.6M$239.6M$117.3M
Common stock$10K$10K$10K$0.00$0.00
Retained earnings-$-1.48B-$-1.26B-$-928.68M-$-727.09M-$-529.37M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity-$-438.17M-$-253.58M-$-72.76M-$-74.81M$72.2M
Total investments$0.00$0.00$0.00$510K$0.00
Total debt$211.8M$201.9M$139M$97.1M$91.3M
Net debt$81.8M-$-95.35M-$-242.36M-$-58.31M-$-91.92M
Cash flow statement
20252024202320222021
Net income-$-221.25M-$-334.33M-$-201.59M-$-197.72M-$-143.88M
Depreciation and amortization$630K$800K$570K$620K$520K
Stock-based compensation$28.7M$24.1M$45M$24.1M$16.8M
Change in working capital-$-12.38M-$-15.3M-$-13.64M$5.44M-$-27.32M
Accounts receivable-$-39.33M-$-37.16M-$-1.64M$0.00$0.00
Inventory-$-11.78M-$-6.14M-$-9.44M$0.00$0.00
Accounts payable$34.1M$34.9M$6.41M$8.68M-$-9.79M
Net cash provided by operating activities-$-166.78M-$-266.77M-$-137.58M-$-146.53M-$-148.46M
Investments in property, plant and equipment-$-230K-$-140K-$-1.63M-$-1.04M-$-330K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-230K-$-140K-$-1.63M-$-1.04M-$-330K
Common stock issued$1.64M$121.8M$155.5M$24.6M$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-290K$182.8M$367.6M$120M$44.7M
Net change in cash-$-167.29M-$-84.13M$228.4M-$-27.87M-$-104.08M
Cash at end of period$132.8M$300.1M$384.3M$155.4M$183.4M
Operating cash flow-$-166.78M-$-266.77M-$-137.58M-$-146.53M-$-148.46M
Capital expenditure-$-230K-$-140K-$-1.63M-$-1.04M-$-330K
Free cash flow-$-166.78M-$-266.9M-$-139.21M-$-147.57M-$-148.78M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Phathom Pharmaceuticals, Inc.

        Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey.

        CEO
        Steven L. Basta
        Employees
        371
        Beta
        0.49

        Explore

        Frequently asked questions

        What is the intrinsic value of Phathom Pharmaceuticals, Inc. (PHAT)?

        Phathom Pharmaceuticals, Inc. (PHAT) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is PHAT undervalued?

        PHAT trades at a price of $4.66 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.